Linked Life Data

17326221

Source:http://linkedlifedata.com/resource/pubmed/id/17326221

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-5
pubmed:abstractText
Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<1,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among posttransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%, 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among patients who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patients who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe in wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1527-6465
pubmed:author
pubmed:copyrightInfo
(c) 2007 AASLD.
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
349-60
pubmed:meshHeading
pubmed-meshheading:17326221-Adenine, pubmed-meshheading:17326221-Adult, pubmed-meshheading:17326221-Antiviral Agents, pubmed-meshheading:17326221-DNA, Viral, pubmed-meshheading:17326221-Drug Resistance, Viral, pubmed-meshheading:17326221-Drug Therapy, Combination, pubmed-meshheading:17326221-Female, pubmed-meshheading:17326221-Hepatitis B, pubmed-meshheading:17326221-Hepatitis B virus, pubmed-meshheading:17326221-Humans, pubmed-meshheading:17326221-Kidney Diseases, pubmed-meshheading:17326221-Lamivudine, pubmed-meshheading:17326221-Liver Transplantation, pubmed-meshheading:17326221-Male, pubmed-meshheading:17326221-Middle Aged, pubmed-meshheading:17326221-Phosphonic Acids, pubmed-meshheading:17326221-Prospective Studies, pubmed-meshheading:17326221-Recurrence, pubmed-meshheading:17326221-Waiting Lists
pubmed:year
2007
pubmed:articleTitle
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
pubmed:affiliation
Center for Liver Diseases, University of Miami, Miami, FL 33136, USA. Eschiff@med.miami.edu
pubmed:publicationType
Journal Article, Clinical Trial